BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Black Diamond Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$1.81+0.09 (+5.23%)

Close on Oct 19, 2026

Market cap: $103.83M
P/E (TTM): –
Dividend yield: –

Black Diamond Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Cash & Equivalents	21	37	57	35	67	36	155	52	7.88
Short-Term Investments	108	62	75	88	144	280	0	–	–
Cash & Short-Term Investments	129	99	132	124	211	316	155	52	7.88
Prepaid Expenses & Other	3.79	2.60	2.63	4.90	5.92	4.49	1.05	0.02	–
Total Current Assets	132	101	134	128	216	320	156	52	–
Property, Plant & Equipment	0.37	1.39	1.73	2.59	3.04	0.39	0.16	0.13	–
Gross Property, Plant & Equipment	1.59	2.53	2.53	3.34	3.40	0.55	0.28	0.23	–
Accumulated Depreciation	-1.23	-1.14	-0.80	-0.75	-0.37	-0.16	-0.11	-0.10	–
Long-Term Investments	–	–	–	–	–	–	0	–	–
Operating Lease Right-of-Use Assets	9.30	19	22	25	28	8.40	–	–	–
Other Long-Term Assets	0.07	0.25	0	0	0.02	0.11	0.06	0.01	–
Total Assets	143	123	159	156	248	330	158	52	–
Accounts Payable	0.58	4.01	2.32	1.88	4.11	2.54	1.96	0.42	–
Accrued Expenses	15	17	17	13	20	12	2.90	0.45	–
Current Portion of Leases	3.71	3.40	3.11	2.84	0.32	1.05	–	–	–
Total Current Liabilities	16	21	20	15	24	14	4.86	2.58	–
Long-Term Leases	15	19	22	25	28	7.69	–	–	–
Operating Lease Liabilities	19	22	25	28	29	8.74	–	–	–
Total Liabilities	31	39	42	41	52	22	4.88	6.60	–
Preferred Stock	0	0	0	0	0	0	0	–	–
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.00	–
Additional Paid-In Capital	577	570	534	453	440	425	3.81	0.17	–
Retained Earnings	-465	-487	-417	-335	-244	-118	-51	-16	–
Comprehensive Income & Other	0.10	0.02	-0.03	-1.82	-0.41	0.61	0	–	–
Shareholders' Equity	112	83	117	116	196	308	-47	-16	-6.68
Total Equity	112	83	117	116	196	308	-47	-16	-6.68
Total Liabilities & Equity	143	123	159	156	248	330	158	52	–
Shares Outstanding(shares)	57	57	52	36	36	36	2.24	2.17	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 22.9%

Financial strength

Current ratio: 7.28
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 121.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.08
Dividend yield: –